Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 2,767 full-time employees. The company went IPO on 2010-10-28. The firm operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The firm conducts its business in the domestic and overseas markets.
Sihuan Pharmaceutical Holdings Group Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Sihuan Pharmaceutical Holdings Group Ltd 주요 수익원은 Generic Medicine이며, 최신 수익 발표에서 수익은 1,191,874,310입니다. 지역별로는 China이 Sihuan Pharmaceutical Holdings Group Ltd의 주요 시장이며, 수익은 2,047,607,773입니다.
Sihuan Pharmaceutical Holdings Group Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 Sihuan Pharmaceutical Holdings Group Ltd의 순손실은 $-216입니다.
Sihuan Pharmaceutical Holdings Group Ltd에 부채가 있나요?
예, Sihuan Pharmaceutical Holdings Group Ltd의 부채는 6,159입니다.
Sihuan Pharmaceutical Holdings Group Ltd의 발행 주식은 몇 주인가요?
Sihuan Pharmaceutical Holdings Group Ltd의 총 발행 주식은 9,244.06주입니다.